Nivolumab is a monoclonal antibody and a PD-1 inhibitor (programmed death receptor inhibitor) which is prescribed for cancer treatment. The therapeutic efficacy of Bacillus calmette-guerin ...

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

Nivolumab was first evaluated in a phase I ... with 52% of participants achieving a complete response. No grade 3/4 side effects were observed (Westin et al, 2010). Patients with heavily ...

You have pembrolizumab every 6 weeks or nivolumab and ipilimumab every 4 weeks. You have it as a drip into a vein. You have treatment for up to 2 years as long as it is working and the side effects ...

GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Elizabeth Plimack discussing two abstracts: “Adjuvant nivolumab vs placebo for high-risk ...

and most severe side effects being adrenal insufficiency. The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer.